Abstract: Described herein are epigenetic modulators that modulate expression of voltage gated sodium channels, such as Nav1.7 and Nav1.8, without editing the genetic sequence. An epigenetic modulator may include a nucleic acid-binding agent that binds to a target sequence within a gene encoding the voltage gated sodium channel and an expression modulating agent that modulates expression of the gene. Also described herein are methods of treating inflammation, pain, or both using an epigenetic modulator of Nav1.7 or Nav1.8.

Abstract: The present disclosure provides complexes comprising: i) a cationic oligosaccharide comprising one or more cationic moieties bonded to a trehalose, a sucrose, or a gluco-n-oligosaccharide moiety, where n is 2-6; ii) a surfactant; and iii) one or more additives selected from: a sterol, a helper lipid, an immunomodulator, and a targeting molecule; and uses thereof.

Abstract: A method (200) is disclosed for orchestrating management of a plurality of operational parameters in an environment of a communication network. Each of the operational parameters is managed by a respective Agent, and at least one performance parameter of the communication network is operable to be impacted by each of the operational parameters. The method comprises obtaining a representation of a state of the environment (210), and generating a prediction, using an ML process and the obtained state representation, of which of the Agents, if allowed to execute within the environment an action selected by the Agent for management of its operational parameter, will result in the greatest increase of a performance measure for the communication network (220). The method further comprises selecting an Agent on the basis of the prediction (230) and initiating execution by the selected Agent of its selected action (240).

Abstract: The invention relates to a workspace wall (1) for placement on a desk to reduce noise within a noise reduction area (7) in an operating orientation (11). The workspace wall (1) comprises a main wall element (3), at least one wing panel (4), optionally at least one sound detection element (21) for detecting a sound signal input (12), and at least one sound generating device (22), preferably for active noise reduction and/or a passive noise reduction element (20). The at least one sound generating device (22) and/or the passive noise reduction element (20) is configured to reduce the level of noise within the noise reduction area (7). (FIG.

Abstract: Compounds, e.g., radioimmunoconjuguates including a chelating moiety or a metal complex thereof, a linker, and an EGFRVIII targeting moiety. Pharmaceutical compositions of such compounds and methods of treatment for conditions. e.g., cancer, using such compounds or pharmaceutical compositions.

Abstract: Antigen-binding agents such as humanized antibodies or antigen-binding fragments thereof, that specifically bind to epidermal growth factor receptor variant III (EGFRvIII) are provided. The EGFRVIII-specific humanized antibodies or antigen-binding fragments thereof may be used for the treatment of cancer.

Abstract: Described herein are compositions and methods to modulate gene expression without permanently editing the genome. The compositions and methods may be useful to treat neurological diseases and pain.

Abstract: Provided herein are compositions and methods for treating metabolic disorders, such as hepatic steatosis, adipose tissue dysfunction, and insulin resistance. Small interfering RNAs (siRNAs) targeting LPS-binding protein (LBP) that include unlocked nucleotides (UNA) and their therapeutic applications for the treatment of metabolic disorders are provided herein.

Abstract: The present disclosure concerns antibodies specific for the Na v.7 polypeptides which are capable of antagonizing the biological activity of the Na v.7 polypeptide. The anti-Na v.7 antibodies can be used for alleviating the symptoms of pain and/or for treating or alleviating the symptoms of an hyperproliferative disease. The presence disclosure also concerns immunogens and methods for making antibodies, such as the anti-Na v.7 antibodies, comprising a single-domain antibody.

Abstract: An occlusive device, occlusive device delivery system, method of using, and method of delivering an occlusive device, and method of making an occlusive device to treat various intravascular conditions is described.

Abstract: An occlusive device, occlusive device delivery system, method of using, and method of delivering an occlusive device, and method of making an occlusive device to treat various intravascular conditions is described.

Abstract: Antigen-binding agents such as antibodies or antigen-binding fragments thereof, chimeric antigen receptors (CARs), bispecific T-cell engagers (BiTEs) and the like that specifically bind to epidermal growth factor receptor variant III (EGFRvIII) are provided. The EGFRvIII-specific antibodies or antigen-binding fragments, CARs and BiTEs thereof may be used for the treatment of cancer. Antibody drug conjugates targeting EGFRvIII-expressing cells are particularly contemplated.

Abstract: The present invention provides cystobactamides of formula (I): R1—Ar1-L1-Ar2-L2-Ar3-L3-Ar4-L4-Ar5—R2 and the use thereof for the treatment or prophylaxis of bacterial infections.

Abstract: The present invention pertains to genetically modified plants, particularly maize, sorghum and rice, with an all pistillate or all staminate phenotype and methods of the same. The survival of functional pistils in maize requires the action of the sk1 gene. SK1 encodes a glycosyltransferase (GT) that protects pistils from tasselseed-mediated cell death. sk1-dependent pistil protection at a developing floret gives rise to stamen arrest at the same floret, and so determines the pistillate floral fate. This is the first single gain-of-function gene known to control sexuality. The present invention further provides a direct strategy to extend hybrid technologies to related cereals such as sorghum and rice. Tasselseed and silkless genes represent major sex determination genes in maize, a pathway that permits the efficient production of hybrid seed and the associated benefits of heterosis-increased yield, resistance to pathogens, etc.

Abstract: The present disclosure concerns antibodies specific for the Na v.7 polypeptides which are capable of antagonizing the biological activity of the Na v.7 polypeptide. The anti-Na v.7 antibodies can be used for alleviating the symptoms of pain and/or for treating or alleviating the symptoms of an hyperproliferative disease. The presence disclosure also concerns immunogens and methods for making antibodies, such as the anti-Na v.7 antibodies, comprising a single-domain antibody.

Abstract: The present invention provides cystobactamides of formula (I): R1—Ar1-L1-Ar2-L2-Ar3-L3-Ar4-L4-Ar5—R2 and the use thereof for the treatment or prophylaxis of bacterial infections.

Abstract: An occlusive device, occlusive device delivery system, method of using, and method of delivering an occlusive device, and method of making an occlusive device to treat various intravascular conditions is described.

Abstract: The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections.

Abstract: An occlusive device, occlusive device delivery system, method of using, and method of delivering an occlusive device, and method of making an occlusive device to treat various intravascular conditions is described.

Abstract: The present invention provides a method for the treatment or prophylaxis of bacterial infections by administering to a subject in need thereof an effective amount of a compound of formula.